Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory

Jang June Park, Sudarshan Anand, Yuming Zhao, Yumiko Matsumura, Yukimi Sakoda, Atsuo Kuramasu, Scott E. Strome, Lieping Chen, Koji Tamada

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Genetic engineering of tumor cells to express immune-stimulatory molecules, including cytokines and co-stimulatory ligands, is a promising approach to generate highly efficient cancer vaccines. The co-signaling molecule, LIGHT, is particularly well suited for use in vaccine development as it delivers a potent co-stimulatory signal through the Herpes virus entry mediator (HVEM) receptor on T cells and facilitates tumor-specific T cell immunity. However, because LIGHT binds two additional receptors, lymphotoxin β receptor and Decoy receptor 3, there are significant concerns that tumor-associated LIGHT results in both unexpected adverse events and interference with the ability of the vaccine to enhance antitumor immunity. In order to overcome these problems, we generated tumor cells expressing the single-chain variable fragment (scFv) of anti-HVEM agonistic mAb on the cell surface. Tumor cells expressing anti-HVEM scFv induce a potent proliferation and cytokine production of co-cultured T cells. Inoculation of anti-HVEM scFv-expressing tumor results in a spontaneous tumor regression in CD4+ and CD8+ T cell-dependent fashion, associated with the induction of tumor-specific long-term memory. Stimulation of HVEM and 4-1BB co-stimulatory signals by anti-HVEM scFv-expressing tumor vaccine combined with anti-4-1BB mAb shows synergistic effects which achieve regression of pre-established tumor and T cell memory specific to parental tumor. Taken in concert, our data suggest that genetic engineering of tumor cells to selectively potentiate the HVEM signaling pathway is a promising antitumor vaccine therapy.

Original languageEnglish (US)
Pages (from-to)203-214
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume61
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Single-Chain Antibodies
Virus Internalization
Long-Term Memory
Immunity
Neoplasms
T-Lymphocytes
Cancer Vaccines
Genetic Engineering
Light
Vaccines
Cytokines
Active Immunotherapy
Lymphotoxin-alpha
Aptitude
T-Cell Antigen Receptor
Cultured Cells

Keywords

  • Co-stimulation
  • HVEM
  • scFv
  • T cell memory
  • Tumor immunity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory. / Park, Jang June; Anand, Sudarshan; Zhao, Yuming; Matsumura, Yumiko; Sakoda, Yukimi; Kuramasu, Atsuo; Strome, Scott E.; Chen, Lieping; Tamada, Koji.

In: Cancer Immunology, Immunotherapy, Vol. 61, No. 2, 02.2012, p. 203-214.

Research output: Contribution to journalArticle

Park, Jang June ; Anand, Sudarshan ; Zhao, Yuming ; Matsumura, Yumiko ; Sakoda, Yukimi ; Kuramasu, Atsuo ; Strome, Scott E. ; Chen, Lieping ; Tamada, Koji. / Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory. In: Cancer Immunology, Immunotherapy. 2012 ; Vol. 61, No. 2. pp. 203-214.
@article{cb8b81b69c4b4e0695dfab7fc4baf33c,
title = "Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory",
abstract = "Genetic engineering of tumor cells to express immune-stimulatory molecules, including cytokines and co-stimulatory ligands, is a promising approach to generate highly efficient cancer vaccines. The co-signaling molecule, LIGHT, is particularly well suited for use in vaccine development as it delivers a potent co-stimulatory signal through the Herpes virus entry mediator (HVEM) receptor on T cells and facilitates tumor-specific T cell immunity. However, because LIGHT binds two additional receptors, lymphotoxin β receptor and Decoy receptor 3, there are significant concerns that tumor-associated LIGHT results in both unexpected adverse events and interference with the ability of the vaccine to enhance antitumor immunity. In order to overcome these problems, we generated tumor cells expressing the single-chain variable fragment (scFv) of anti-HVEM agonistic mAb on the cell surface. Tumor cells expressing anti-HVEM scFv induce a potent proliferation and cytokine production of co-cultured T cells. Inoculation of anti-HVEM scFv-expressing tumor results in a spontaneous tumor regression in CD4+ and CD8+ T cell-dependent fashion, associated with the induction of tumor-specific long-term memory. Stimulation of HVEM and 4-1BB co-stimulatory signals by anti-HVEM scFv-expressing tumor vaccine combined with anti-4-1BB mAb shows synergistic effects which achieve regression of pre-established tumor and T cell memory specific to parental tumor. Taken in concert, our data suggest that genetic engineering of tumor cells to selectively potentiate the HVEM signaling pathway is a promising antitumor vaccine therapy.",
keywords = "Co-stimulation, HVEM, scFv, T cell memory, Tumor immunity",
author = "Park, {Jang June} and Sudarshan Anand and Yuming Zhao and Yumiko Matsumura and Yukimi Sakoda and Atsuo Kuramasu and Strome, {Scott E.} and Lieping Chen and Koji Tamada",
year = "2012",
month = "2",
doi = "10.1007/s00262-011-1101-8",
language = "English (US)",
volume = "61",
pages = "203--214",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory

AU - Park, Jang June

AU - Anand, Sudarshan

AU - Zhao, Yuming

AU - Matsumura, Yumiko

AU - Sakoda, Yukimi

AU - Kuramasu, Atsuo

AU - Strome, Scott E.

AU - Chen, Lieping

AU - Tamada, Koji

PY - 2012/2

Y1 - 2012/2

N2 - Genetic engineering of tumor cells to express immune-stimulatory molecules, including cytokines and co-stimulatory ligands, is a promising approach to generate highly efficient cancer vaccines. The co-signaling molecule, LIGHT, is particularly well suited for use in vaccine development as it delivers a potent co-stimulatory signal through the Herpes virus entry mediator (HVEM) receptor on T cells and facilitates tumor-specific T cell immunity. However, because LIGHT binds two additional receptors, lymphotoxin β receptor and Decoy receptor 3, there are significant concerns that tumor-associated LIGHT results in both unexpected adverse events and interference with the ability of the vaccine to enhance antitumor immunity. In order to overcome these problems, we generated tumor cells expressing the single-chain variable fragment (scFv) of anti-HVEM agonistic mAb on the cell surface. Tumor cells expressing anti-HVEM scFv induce a potent proliferation and cytokine production of co-cultured T cells. Inoculation of anti-HVEM scFv-expressing tumor results in a spontaneous tumor regression in CD4+ and CD8+ T cell-dependent fashion, associated with the induction of tumor-specific long-term memory. Stimulation of HVEM and 4-1BB co-stimulatory signals by anti-HVEM scFv-expressing tumor vaccine combined with anti-4-1BB mAb shows synergistic effects which achieve regression of pre-established tumor and T cell memory specific to parental tumor. Taken in concert, our data suggest that genetic engineering of tumor cells to selectively potentiate the HVEM signaling pathway is a promising antitumor vaccine therapy.

AB - Genetic engineering of tumor cells to express immune-stimulatory molecules, including cytokines and co-stimulatory ligands, is a promising approach to generate highly efficient cancer vaccines. The co-signaling molecule, LIGHT, is particularly well suited for use in vaccine development as it delivers a potent co-stimulatory signal through the Herpes virus entry mediator (HVEM) receptor on T cells and facilitates tumor-specific T cell immunity. However, because LIGHT binds two additional receptors, lymphotoxin β receptor and Decoy receptor 3, there are significant concerns that tumor-associated LIGHT results in both unexpected adverse events and interference with the ability of the vaccine to enhance antitumor immunity. In order to overcome these problems, we generated tumor cells expressing the single-chain variable fragment (scFv) of anti-HVEM agonistic mAb on the cell surface. Tumor cells expressing anti-HVEM scFv induce a potent proliferation and cytokine production of co-cultured T cells. Inoculation of anti-HVEM scFv-expressing tumor results in a spontaneous tumor regression in CD4+ and CD8+ T cell-dependent fashion, associated with the induction of tumor-specific long-term memory. Stimulation of HVEM and 4-1BB co-stimulatory signals by anti-HVEM scFv-expressing tumor vaccine combined with anti-4-1BB mAb shows synergistic effects which achieve regression of pre-established tumor and T cell memory specific to parental tumor. Taken in concert, our data suggest that genetic engineering of tumor cells to selectively potentiate the HVEM signaling pathway is a promising antitumor vaccine therapy.

KW - Co-stimulation

KW - HVEM

KW - scFv

KW - T cell memory

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84856753480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856753480&partnerID=8YFLogxK

U2 - 10.1007/s00262-011-1101-8

DO - 10.1007/s00262-011-1101-8

M3 - Article

C2 - 21877247

AN - SCOPUS:84856753480

VL - 61

SP - 203

EP - 214

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -